Impact Therapeutics aims to raise up to $117M in a Hong Kong IPO, according to a Tuesday morning term sheet. The China-based oncology firm is offering 41.98M shares priced between HK$19.75 and HK$21.75. This offering tests investor appetite for clinical-stage biotech as Singapore and regional hubs track listing volumes.

Cornerstone Support and Deal Structure